The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Initial uptake of durvalumab with or without tremelimumab for advanced hepatocellular carcinoma in routine clinical practice: Preliminary results of the international DT-real study.
 
Ciro Celsa
Speakers' Bureau - AstraZeneca; Eisai; MSD
Research Funding - European Regional Development Fund
 
Naoshi Nishida
No Relationships to Disclose
 
Ashwini Arvind
No Relationships to Disclose
 
Susanna Varkey Ulahannan
Consulting or Advisory Role - AstraZeneca; Eisai; IgM Biosciences
Research Funding - Abbvie (Inst); Adlai Nortye (Inst); ArQule (Inst); Astex Pharmaceuticals (Inst); AstraZeneca (Inst); atreca (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); Celgene (Inst); CicloMed (Inst); Erasca, Inc (Inst); evelo biosciences (Inst); Exelixis (Inst); Exelixis (Inst); G1 Therapeutics (Inst); GlaxoSmithKline (Inst); IgM Biosciences (Inst); Incyte (Inst); Klus Pharma (Inst); Macrogenics (Inst); Merck (Inst); Mersana (Inst); NGM Biopharmaceuticals (Inst); OncoMed (Inst); Pfizer (Inst); Pionyr (Inst); Regeneron (Inst); Revolution Medicines (Inst); Synermore biologics (Inst); Takeda (Inst); Takeda (Inst); Tarveda Therapeutics (Inst); Tempest Therapeutics (Inst); Tesaro (Inst); Vigeo Therapeutics (Inst)
 
Michael Li
No Relationships to Disclose
 
Bernhard Scheiner
Travel, Accommodations, Expenses - Abbvie; Gilead Sciences; Ipsen
 
Claudia A.M. Fulgenzi
No Relationships to Disclose
 
Antonio D'Alessio
Consulting or Advisory Role - AstraZeneca; Roche
Speakers' Bureau - Roche
Travel, Accommodations, Expenses - Roche
 
Giulia F Manfredi
No Relationships to Disclose
 
Bernardo Stefanini
No Relationships to Disclose
 
Giuseppe Cabibbo
Consulting or Advisory Role - AstraZeneca; Bayer; Eisai; Ipsen; Roche
 
Alessio Cortellini
Consulting or Advisory Role - AstraZeneca; Bristol-Myers Squibb; IQvia; MSD Oncology; OncoC4
Speakers' Bureau - AstraZeneca; Eisai
 
Matthias Pinter
Honoraria - Bayer; Eisai; Lilly; MSD; Roche
Consulting or Advisory Role - AstraZeneca; Bayer; Bristol-Myers Squibb; Eisai; Ipsen; Lilly; MSD; Roche
Travel, Accommodations, Expenses - Bayer; Bristol-Myers Squibb; Roche
 
Robin Kate Kelley
Consulting or Advisory Role - Agios (Inst); AstraZeneca (Inst); Compass Therapeutics; Elevar Therapeutics; Exelixis/Ipsen (Inst); Kinnate Biopharma; Merck (Inst); Regeneron; Tyra Biosciences
Research Funding - Adaptimmune (Inst); Agios (Inst); AstraZeneca (Inst); Bayer (Inst); Bristol-Myers Squibb (Inst); Compass Therapeutics (Inst); EMD Serono (Inst); Exelixis (Inst); Genentech/Roche (Inst); Lilly (Inst); Loxo/Lilly (Inst); MedImmune (Inst); Merck Sharp & Dohme (Inst); Novartis (Inst); Partner Therapeutics (Inst); QED Therapeutics (Inst); Relay Therapeutics (Inst); SERVIER (Inst); Surface Oncology (Inst); Taiho Pharmaceutical (Inst)
Travel, Accommodations, Expenses - AstraZeneca; Merck
 
Paul Antoine El Tomb
No Relationships to Disclose
 
Amit G. Singal
Consulting or Advisory Role - AstraZeneca; Bayer; BMSi; Eisai; Exact Sciences; Exelixis; FjuFilm Medical Sciences; Genentech; Glycotest; GRAIL; Roche
 
Masatoshi Kudo
Honoraria - AstraZeneca; Bayer; Chugai/Roche; Eisai; Lilly Japan; Takeda
Consulting or Advisory Role - AstraZeneca; Chugai/Roche; Eisai
Research Funding - Abbvie (Inst); Chugai/Roche (Inst); EA Pharma (Inst); Eisai (Inst); GE Healthcare (Inst); Gilead Sciences (Inst); Otsuka (Inst); Taiho Pharmaceutical (Inst)
 
David James Pinato
Honoraria - Avammune; Bristol-Myers Squibb; Da Volterra; Lift Biosciences; Mursla Bio; Roche/Genentech; Starpharma
Consulting or Advisory Role - AstraZeneca; Da Volterra; EISAI; H3 Biomedicine; Ipsen; Mina Therapeutics; Roche
Speakers' Bureau - Bayer; Falk Pharma; Roche; ViiV Healthcare
Research Funding - Bristol-Myers Squibb (Inst); GlaxoSmithKline (Inst); MSD Oncology (Inst)
Travel, Accommodations, Expenses - Bayer; Bristol-Myers Squibb; MSD Oncology
Other Relationship - Wiley